Meg Guard, Alyssa K Labonte, Molly Mendoza, Michael J Myers, Maida Duncan, Andrew T Drysdale, Emily Mukherji, Tahir Rahman, Mini Tandon, Jeannie C Kelly, Emily Cooke, Cynthia E Rogers, Shannon Lenze, Chad M Sylvester
PURPOSE/BACKGROUND: Brexanolone is approved for postpartum depression (PPD) by the United States Food and Drug Administration. Brexanolone has outperformed placebo in clinical trials, but less is known about the efficacy in real-world patients with complex social and medical histories. Furthermore, the impact of brexanolone on large-scale brain systems such as changes in functional connectivity (FC) is unknown. METHODS/PROCEDURES: We tracked changes in depressive symptoms across a diverse group of patients who received brexanolone at a large medical center...
March 29, 2024: Journal of Clinical Psychopharmacology